World Health Organization Sounds Concern Over Critical Lack of Obesity Injections

Less than 10% of patients that would benefit from obesity jabs including Wegovy are able to get them, warns the World Health Organization as it publishes its initial advice on the drugs.

Considering more than one billion individuals worldwide currently living with obesity, it is calling for broader and more equitable availability to this class of drugs.

Based on forecasts, over two billion will be living with obesity by 2030 unless action is taken.

"The new guidelines affirms that excess weight is a long-term condition that can be addressed with thorough and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and distribution challenges are significant obstacles to widespread availability to the treatments that can assist patients in reducing considerable weight, explains the organization.

Weight-Loss Drug Scarcity

Despite the present most favorable outlook, the supply of these medications could only cover approximately 100 million people – under 10% of eligible patients, as stated by the health organization.

The recommendation encourages nations and manufacturers to increase access, via strategies including voluntary licensing.

Exclusive production rights on the active ingredient – the main ingredient of the drug Wegovy – is scheduled to end in several nations in 2026.

The Way Obesity Jabs Operate

The injections replicate a natural hormone to reduce digestion speed, reduce hunger and increase satiety so users eat less.

People typically begin shedding pounds after several weeks of beginning the regular doses.

Studies points to patients may regain a significant portion after a year of stopping the drug, because their usual appetite resume.

Being carrying excess weight increases your risk for experiencing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.

Obesity affects people in every country and was responsible for over three and a half million fatalities worldwide in 2024, per the WHO.